81250-24-0Relevant academic research and scientific papers
Modified 3-alkyl-1,8-dibenzylxanthines as GTP-competitive inhibitors of phosphoenolpyruvate carboxykinase
Foley, Louise H.,Wang, Ping,Dunten, Pete,Ramsey, Gwendolyn,Gubler, Mary-Lou,Wertheimer, Stanley J.
, p. 3607 - 3610 (2007/10/03)
The first non-substrate like inhibitors of human cytosolic phosphoenolpyruvate carboxykinase (PEPCK) competitive with GTP are reported. An effort to discover orally active compounds that improve glucose homeostasis in Type 2 diabetics by reversibly inhibi
Di- or trisubstituted xanthines with neuroleptic properties and composition
-
, (2008/06/13)
The invention relates to xanthines corresponding to the formula STR1 and physiologically acceptable salts thereof, in which R1 represents C2 -C4 -alkyl, C3 -C4 -isoalkyl, CH2 -(C2 -C3 -alkenyl) or CH2 -(C3 -isoalkenyl); R3 represents C3 -C5 -alkyl, C3 -C5 -isoalkyl, CH2 -(C2 -C4 -alkenyl) or CH2 -(C3 -C4 -isoalkenyl); R8 represents H, methyl or ethyl; with the proviso that (1) when R8 represents H, R1 is allyl and (2) R1 and R3 cannot both represent butyl or allyl at the same time. The compounds show non-specific or anxiolytic sedative activity.
